INKON Life Technology Co., Ltd. Class A

INKON Life Technology Co., Ltd. Class A

SSZSE:300143
6.91
CNY
-0.13
(-1.85%)
0.12EPS
90.81P/E
7.64BMarket Cap
Apr 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.7
0.85
0.75
0.7
0.48
0.7
0.81
1.33
1.31
1.51
1.8
1.87
1.9
2.13
Basic EPS, GAAP
-0.45
-0.81
0.03
0.09
0.18
0.07
-0.99
0.19
-0.44
-0.78
0.12
0.14
0.07
0.09
Free Cash Flow per Basic Share
-0.39
-0.09
0.05
0.03
0.15
0.1
- -
0.03
0.08
0.05
0.04
0.07
0.12
- -
Dividend per Share
0.04
0.06
0.05
0.03
- -
0.01
0.04
0.03
0.01
0.04
- -
0.01
0.01
0.05
Book Value per Share
1.65
0.84
3.96
3.1
3.34
2.87
1.89
3.11
2.12
1.54
1.66
2.49
2.58
2.49
Tangible Book Value per Share
1.48
0.67
0.97
1.59
0.63
0.02
0.09
1.22
0.78
0.6
0.54
1.55
1.32
1.24
Basic Weighted Avg Shares
363
364
373
618
692
725
709
772
830
767
816
834
990
968
Sales/Revenue/Turnover
255
308
280
432
329
504
573
1,029
1,090
1,156
1,471
1,559
1,886
2,061
Operating Margin (%)
-29.66
-16.82
6.64
18.27
34.7
26.7
17.33
11.35
7.02
10.33
11.31
10.08
12.27
13.1
Depreciation Expense
48
57
40
57
30
40
47
40
59
56
76
89
109
- -
Net Income, GAAP
-163
-293
11
55
122
50
-703
149
-364
-596
100
115
69
84
Effective Tax Rate (%)
- -
- -
- -
23.72
16.17
26.56
- -
25.52
- -
- -
24.58
22.3
42.4
38.06
Profit Margin (%)
-64.02
-95.27
3.78
12.74
37.18
9.95
-122.77
14.44
-33.41
-51.54
6.83
7.4
3.64
4.06
Working Capital
-149
-190
18
1,095
236
63
23
800
342
216
153
1,036
945
1,077
LT Debt
127
74
51
- -
- -
350
250
462
92
78
109
223
607
704
Total Equity
643
344
1,484
2,196
2,433
2,067
1,367
2,627
1,805
1,317
1,429
2,478
2,616
2,490
Return on Invested Capital (%)
- -
- -
-0.42
1.91
5.71
2.77
- -
2.09
- -
- -
6.83
4.44
3.08
- -
Return on Capital (%)
- -
- -
2.24
3.77
4.51
1.45
- -
6.53
- -
- -
6.8
5.46
1.97
- -
Return on Common Equity (%)
-23.95
-64.73
1.21
3.06
5.39
2.27
-41.63
7.55
-16.66
-38.99
7.54
6.06
2.77
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
142
106
101
LT Borrowings
442
564
543
LT Finance Leases
167
164
161
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
974
973
973
Market Capitalization
9,458
6,558
7,638

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,833
1,774
1,803
Cash, Cash Equivalents & STI
1,309
1,252
1,074
Accounts Receivable, Net
262
239
235
Inventories
89
82
94
Total Current Liabilities
829
747
726
Payables & Accruals
- -
- -
- -
ST Debt
142
106
101
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.11%
5.83%
5.57%
Free Cash Flow
139.28%
67.15%
88.49%
Net Income, GAAP
-156.33%
-84.8%
-40.62%
Sales/Revenue/Turnover
24.3%
13.23%
20.93%
Total Cash Common Dividend
- -
151.14%
21.56%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
416
407
404
332
1,559
2025
409
434
- -
528
1,886
2026
496
520
517
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.04
0.14
2025
0.03
0.03
- -
-0.02
0.07
2026
0.03
0.04
0.04
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
0.03
0.01
- -
- -

Company Description

CEO
Anjie Ma
Full Time Employees
2,662
Sector
Health technology
Industry
Medical specialties
Address
Qingdao China
IPO Date
Nov 26, 2010
Business
INKON Life Technology Co., Ltd. is a China-based healthcare technology and medical services enterprise that operates an integrated oncology and clinical care ecosystem encompassing medical device manufacturing and healthcare facility operations. Founded in 1998 and headquartered in Dongguan, China, and operating as a core clinical healthcare platform under the Haier Group ecosystem, the company serves healthcare institutions and patients domestically and internationally across the continuum of cancer prevention, screening, diagnosis, treatment, and rehabilitation. INKON Life Technology operates primarily through two business segments: Medical Equipment and Medical Services. The Medical Equipment segment researches, manufactures, and distributes advanced radiotherapy, imaging, and life support systems, including stereotactic gamma-ray radiosurgery systems such as head and body Gamma Knife devices developed through its subsidiary Masep Medical Science and Technology; high-pressure contrast media delivery injectors, including the Discovery D series for computed tomography, magnetic resonance imaging, and digital subtraction angiography, along with matching syringe and tubing consumables produced via its Shenzhen Saintnode Medical subsidiary; AI-assisted digital mammography systems for early tumor screening; and smart infusion pumps, target-controlled infusion devices, and chronic disease management equipment. The Medical Services segment owns, operates, and manages oncology-specialized and general hospitals, offering inpatient and outpatient medical services; surgical oncology; precision stereotactic radiotherapy; medical oncology and chemotherapy; diagnostic laboratory and imaging services; critical care management; and comprehensive post-acute rehabilitation and elderly nursing care across a tiered network of medical centers. In recent developments, INKON Life Technology has accelerated the integration of artificial intelligence and Internet of Things technologies across its clinical solutions, launching AI-enhanced diagnostic mammography platforms and intelligent pressure-monitoring contrast injector systems. The company has also deepened operational synergies and expanded production capabilities following the integration of Shenzhen Saintnode Medical, advanced its proprietary high-end radiotherapy platforms, expanded clinical treatment capacities for complex oncology surgeries across its hospital network, and strategically broadened its institutional service footprint across serious illness treatment, intensive rehabilitation, and eldercare nursing.